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Abstract
Background: Government policy has precipitated recent changes in the provision of harm reduction interventions –
injecting equipment provision (IEP) and opiate substitution therapy (OST) – for people who inject drugs (PWID) in Scotland.
We sought to examine the potential impact of these changes on hepatitis C virus (HCV) transmission among PWID.
Methods and Findings: We used a framework to triangulate different types of evidence: ‘group-level/ecological’ and
‘individual-level’. Evidence was primarily generated from bio-behavioural cross-sectional surveys of PWID, undertaken
during 2008-2012. Individuals in the window period (1–2 months) where the virus is present, but antibodies have not yet
been formed, were considered to have recent infection. The survey data were supplemented with service data on the
provision of injecting equipment and OST. Ecological analyses examined changes in intervention provision, self-reported
intervention uptake, self-reported risk behaviour and HCV incidence; individual-level analyses investigated relationships
within the pooled survey data. Nearly 8,000 PWID were recruited in the surveys. We observed a decline in HCV incidence,
per 100 person-years, from 13.6 (95% CI: 8.1–20.1) in 2008–09 to 7.3 (3.0–12.9) in 2011–12; a period during which increases
in the coverage of OST and IEP, and decreases in the frequency of injecting and sharing of injecting equipment, were
observed. Individual-level evidence demonstrated that combined high coverage of needles/syringes and OST were
associated with reduced risk of recent HCV in analyses that were unweighted (AOR 0.29, 95%CI 0.11–0.74) and weighted for
frequency of injecting (AORw 0.05, 95%CI 0.01–0.18). We estimate the combination of harm reduction interventions may
have averted 1400 new HCV infections during 2008–2012.
Conclusions: This is the first study to demonstrate that impressive reductions in HCV incidence can be achieved among
PWID over a relatively short time period through high coverage of a combination of interventions.
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Introduction
People who inject drugs (PWID) are at risk of contracting the
hepatitis C virus (HCV) through the sharing of injecting
equipment. Harm reduction interventions to prevent the trans-
mission of HCV include opiate substitution therapy (OST), which
aims to help PWID reduce their frequency of, or cease, injecting,
and sterile injecting equipment provision (IEP), which aims to
ensure that any injections that do take place are done with a clean
set of equipment. Needles/syringes have long been implicated in
HCV transmission; however, increasing evidence suggests that
other injecting paraphernalia used in the drug preparation process
(e.g. filters, spoons and water) may also contribute to transmission
[1,2].
Two reviews of the literature have highlighted that there is
insufficient evidence demonstrating the effectiveness of certain
harm reduction interventions – particularly IEP – on HCV
transmission among PWID [3,4]. A few studies have examined the
impact of combining harm reduction interventions [5–7], but
there remains a need to strengthen our understanding of the
effectiveness of OST and IEP [8,9]. Furthermore, previous studies
of the impact of IEP on HCV incidence have focused solely on
sterile needle/syringe provision (NSP); hitherto, no studies to date
have directly examined the impact of providing non-needle/
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syringe injecting paraphernalia (primarily spoons/cookers and
filters) in the prevention of HCV transmission [10].
In 2008, the Scottish Government launched the Hepatitis C
Action Plan for Scotland (Phase II), with one of its three main aims
to prevent HCV transmission among PWID. The main driver for
change was the release of the National IEP Guidelines, which
recommended [11] the provision of a set of new sterile injection
equipment for every injection, and additional dedicated funding
(£3 million per year) awarded to NHS Boards to enable
improvement of services in accordance with these Guidelines.
Contemporaneously to the Action Plan, the Scottish Govern-
ment’s drug and alcohol strategy, Road to Recovery [12], strived
to improve treatment services for those dependent on opiates. In
this paper, we seek to examine the potential impact of these
changes on HCV transmission among PWID: specifically, the aim
is to determine the association between harm reduction interven-
tions (IEP and OST) and incident HCV infection among PWID in
Scotland during 2008 to 2012. To do this, we examine the results
of three national cross-sectional surveys of PWID, as well as data
on IEP and OST provision. These data allow us to examine trends
in uptake of harm reduction interventions, risk behaviour and
HCV incidence. Additionally, the pooling of these surveys
generates the largest sample to have explored HCV transmission
in relation to the combined effects of NSP and OST.
Methods
The difficulties in undertaking what would traditionally be
considered ‘robust’ study designs to investigate public health
interventions have been well documented [13–15]. Nevertheless,
some common themes that have emerged from such evaluations,
in relation to causal attribution, are (i) the importance of
understanding the processes/pathways between intervention(s)
and outcome(s) [16] and (ii) the combination of evidence generated
from different non-experimental study designs [17]. The analytical
approach applied here borrows from these themes: first, to
understand pathways, an analytical framework was produced to
guide the analysis (Figure 1). The objective was to describe each of
the elements of the framework, as well as the relationships between
them, to build an overall picture of the potential mechanisms
between provision of interventions and HCV transmission.
Secondly, in relation to combining evidence from different study
designs, the approach taken here triangulates evidence from
ecological and individual-level approaches (described further
below). All of the information was collated and summarised in a
table, as a means of capturing the evidence for the framework.
Unless otherwise indicated, most of this was derived from analysis
of the surveys described further below.
Data collection
Ethical approval was obtained from the West of Scotland
Research Ethics Service. Three sweeps of a series of cross-sectional
surveys of PWID were undertaken in June 2008–June 2009,
January–November 2010, and March 2011–March 2012. These
voluntary anonymous surveys are collectively called the Needle
Exchange Surveillance Initiative (NESI); the methods have been
described in detail previously [6,18]. Briefly, PWID were recruited
at sites that provide sterile injecting equipment (and often
methadone) across mainland Scotland. People who had ever
injected drugs were eligible to participate, although the majority
(approximately 80%) had injected in the last six months. The
interviewer informed potential participants of the nature of the
study by giving them an information sheet outlining the purpose of
the research and what it would mean to them if they agreed to
participate. Individuals who agreed to participate were then asked
to sign (initials only, to maintain anonymity) a consent form.
Subsequently, participants completed an interviewer-administered
questionnaire and provided a blood spot for laboratory testing.
Data on the provision of OST and IEP in Scotland were
obtained from routine reports published in the grey literature
[19,20].
Laboratory methods
The dried blood spots (DBS) were eluted and tested in a
modification of the Ortho Save 3.0 EIA, which has 99% sensitivity
and 100% specificity for the detection of HCV antibody (anti-
HCV) on DBS [21]. The assay has been adapted further to use
two 3 mm discs punched from DBS and eluted in 200 ml of PBS/
0.05% tween. The optical densities of ,0.4, 0.4–0.79 and $0.8
were classified as negative, equivocal and positive for anti-HCV,
respectively. HCV-RNA testing was undertaken on anti-HCV
negative samples using an ‘in house’ PCR assay [22]; the
sensitivity and specificity of this assay on DBS are 100% and
96%, respectively.
Analysis
Outcome measure
We defined recent HCV infections as individuals who were anti-
HCV negative and HCV-RNA positive. Incidence was derived
using the formula I~
365=Tð Þn
(N{n)z 365=Tð Þnwhere T is the estimated
duration of the window period (where the virus is detectable but
prior to the formation of antibodies), n is the number of recent
infections and N is the number of susceptibles (i.e. anti-HCV
negatives) [6,23]. An estimate of the duration of the window
period (mean 51 days; variance 56 days), was derived from the
literature [24]. Ninety-five percent confidence intervals for the
incidence rates in each survey were generated by bootstrapping: (i)
sampling 1,000 values from each of the binomial and normal
distributions relating to the number of recent infections and the
window period, respectively; (ii) using the sampled values from (i)
in the formula to generate a distribution for the incidence rates;
and (iii) taking the 2.5th and 97.5th percentile values from (ii) to
generate the lower and upper confidence limits.
In order to validate the derived HCV incidence estimates, we
also examined HCV prevalence among those who commenced
injecting within the last 12 months, based on the assumption that
HCV infection will have been acquired since initiation of injecting.
Intervention measures
Variables categorising participants into high and low ‘coverage’
of each injecting equipment item were created by dividing the self-
reported number of items (needles/syringes, spoons, filters, or
water ampoules) obtained in the last six months, by the self-
reported number of injections undertaken in the last six months.
These variables will henceforth be referred to as ‘self-report IEP
coverage’. The threshold for high coverage ($200%) was chosen
on the basis of sensitivity analyses. To reduce collinearity, the
spoon and filter coverage variables were further combined into a
single variable called paraphernalia coverage, such that those who
reported high coverage of both spoons and filters were classified as
having high paraphernalia coverage, with the remaining falling
into the low category; water coverage was not considered since
self-reported sharing of water was not found to be associated with
recent HCV infection in our analyses [2]. Participants were also
categorised by whether they reported being on OST at the time of
the survey (yes/no). OST refers to methadone maintenance as this
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is, overwhelmingly, the primary pharmacological treatment used
to treat opiate addiction in Scotland. Those who reported not
injecting in the last 6 months and no uptake of any interventions
were excluded (n = 157, 2.2% of the pooled sample).
For the purposes of comparing trends over time at the group-
level, an additional coverage measure was calculated by dividing
published numbers of injecting equipment items distributed [19]
by estimates of the total number of injections annually among
Scottish PWID (the latter generated by multiplying the estimated
mean annual number of injections per PWID from NESI with
estimates of the size of the injecting population [25]). This will
henceforth be referred to as ‘service provision IEP coverage’.
Group-level/ecological analysis
We use ‘group-level’ to refer to the statistics that describe the
interventions, intermediate determinants, and outcomes (i.e. the
boxes in Figure 1), and any changes therein. The following were
compared across the three surveys: (i) harm reduction intervention
uptake, (ii) risk behaviour, (iii) HCV prevalence and iv) HCV
incidence. Statistical significance was assessed using either the
Mantel-Haenszel test for trend for categorical variables or
ANOVA for continuous variables. In the ecological analyses,
‘adequate’ coverage was defined as at least one sterile item per
injection (i.e.$100%). In terms of risk behaviour, ‘sharing’ was
defined as the use of an item of injecting equipment after it had
previously been used by someone else.
Respondents who had participated multiple times were
identified from within each survey: 115 (1.4%), 147 (1.8%) and
Figure 1. Analytical framework of potential associations between harm reduction interventions and HCV transmission. The arrows
represent investigated associations: relationships A through C are group-level and relationships D through M are individual-level.
doi:10.1371/journal.pone.0104515.g001
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40 (0.5%) duplicates were excluded from the 2008–09, 2010 and
2011–12 surveys, respectively.
Individual-level analysis
Logistic regression was used to investigate the associations D
through M (Figure 1). Confounding variables that were considered
included survey year, gender, age, homelessness and stimulant
injection (in the last 6 months), time since onset of injecting,
imprisonment (ever) and alcohol consumption (last 12 months). A
backwards stepwise approach to model building was applied;
however, certain variables that had been identified a priori (e.g.
survey year) were included regardless of significance. Analyses
were undertaken in SPSS version 21.
Five multivariable models were built to examine the association
with recent HCV of (self-reported): (i) N/S coverage, (ii)
paraphernalia coverage, (iii) OST, (iv) N/S coverage and OST,
and (v) all three interventions combined. Weighted models were
subsequently run in Stata 9. Sampling weights were set to be equal
to the number of times that a respondent reported injecting in the
six months prior; thus, observations from individuals who reported
injecting more frequently counted more heavily in the analysis.
Sampling weights were increased by one, such that individuals
who reported not injecting in the last 6 months were included
(with a weight of 1).
New infections and infections averted
The number of new chronic infections was estimated for each
calendar year (2008–2012) by combining the derived incidence
rates with published estimates of the size of the PWID population
[25], estimates of anti-HCV prevalence from NESI, and published
estimates of the proportion of HCV-infected individuals who
develop chronic infection (26% on average were assumed to clear
acute infection) [26]. It was assumed that the size of the PWID
population remained stable during this period. The method for
generating a distribution of values for the incidence rates has been
described above. Additionally, posterior distributions for the size of
the PWID population, the proportion anti-HCV negative, and the
proportion that develop chronic infection were generated. One
thousand values were sampled from each of the latter distributions.
The sampled values for the number of PWID were multiplied by
those for the proportion anti-HCV negative, to generate a
distribution for the number of susceptible PWID (i.e. anti-HCV
negatives). The latter were then multiplied by the sampled
incidence values and the sampled values for the proportion
developing chronic infection, to generate a distribution (and 95%
CI, as previously described) for the number of new chronic HCV
infections. An estimate of the number of HCV infections (all and
chronic) potentially averted by harm reduction interventions over
the period 2008–2012 was calculated by subtracting the sum total
of the calculated yearly estimates from that which would have
been observed assuming the number of infections in 2008 had
remained constant.
Results
The average response rate across the surveys was 64%. The
gender distribution was nearly identical between the pooled survey
participants (72% male) and those who refused to participate (73%
male); however, those who refused were slightly younger on
average (31 years) as compared with participants (34 years).
Table 1 summarises the demographic characteristics of the
study population by survey sweep. Significant differences in several
variables were noted between the surveys: mean age increased
from 33.6 in 2008–09 to 35.3 in 2011–12 (P,0.001), as did mean
time since onset of injecting, with respective figures of 10.5 and
11.6 years (P,0.001). The proportion of respondents who
reported homelessness in the last 6 months decreased slightly
from 27% to 22% (P,0.001), as did the proportion who reported
injecting stimulants (23% to 15%, P,0.001).
A summary of the evidence for each of the elements of the
framework is provided in Table 2, and discussed in more detail
below.
Group-level analyses
Firstly, the major changes in provision of interventions (Boxes
1,2, and 3 in Figure 1) that took place were increases in the
provision of filters and spoons by 6-fold and 4-fold, respectively,
between 2008/09 and 2009/10 financial years (Table S1). By
contrast, provision of N/S remained approximately stable over the
period, hovering at around 4.7 million distributed annually, albeit
with minor relative fluctuations. The number of methadone
Table 1. Demographic and other characteristics of study population, by survey.
2008–09 (N=2,629) 2010 (N=3,168) 2011–12 (N=2,154) X2 test (trend) or ANOVAP value
Male gender 72% 72% 73% 0.086 0.770
Mean age in years (SD) 33.6 (7.1) 34.6 (7.3) 35.3 (6.9) F = 35.465 ,0.001
Aged ,25 years 14% 12% 9% 37.000 ,0.001
Homeless in last 6 months 27% 22% 22% 21.370 ,0.001
Injected stimulants in last 6 monthsa 23% 13% 15% 45.416 ,0.001
Ever in prison 59% 61% 61% 2.213 0.137
Excessive alcohol consumptionb (last 12
months)
27% 24% 26% 0.572 0.449
Mean time since onset of injecting
in years (SD)
10.5 (7.4) 11.2 (7.7) 11.6 (7.4) F = 15.247 ,0.001
Commenced injecting within the last 5
years
26% 24% 21% 11.970 0.001
ANOVA= analysis of variance; SD= standard deviation.
aAmong those who reported injecting in the last six months.
bDefined as .14 units/week for women and .21 units/week for men.
doi:10.1371/journal.pone.0104515.t001
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prescriptions dispensed in Scotland increased only slightly up until
2010/11 and then declined by 4% in 2011/12.
In terms of harm reduction intervention uptake (boxes 4
through 6 in Figure 1), the proportion who reported currently
receiving OST increased from 50% to 64% (P,0.001) between
2008–09 and 2011–12 (Table 3). Despite the slight decline in the
median number of sterile needles/syringes obtained (based on self-
report survey data), the proportion of individuals with adequate
N/S coverage was more or less stable (75%–79%) due to
simultaneous declines in frequency of injecting. The proportion
of individuals with adequate coverage of filters and spoons
increased between 2008–09 and 2011–12 (from 24% to 69%
and from 20% to 70%, respectively, both P,0.001). Using the
measure of IEP coverage based on service provision data, the
proportion with adequate N/S, filter, and spoon coverage
increased from 53% to 74%, 4% to 40%, and 6% to 39%,
respectively. These changes were mostly attributable to declines in
the frequency of injecting (Table S2).
The proportion of respondents reporting various risk behaviours
in the last six months declined across the surveys (Table 3):
injecting daily or more frequently (from 63% to 49%, P,0.001),
sharing needles/syringes (from 15% to 8%, P,0.001), reusing
one’s own needles/syringes (64% to 45%, P,0.001), sharing
spoons (42% to 20%, P,0.001), sharing filters (33% to 17%, P,
0.001), and sharing water (31% to 21%, P,0.001).
A total of 53 recent infections were detected among 3,459
susceptible (i.e. anti-HCV negative) individuals. The proportion of
recent HCV infections decreased from 2.1% (95% CI: 1.3%–
3.3%) in 2008–09 to 0.9% (95% CI: 0.4%–1.7%) in 2011–12 (X2
test for trend: P=0.02) (Table 4). The derived incidence rates per
100 person-years (among PWID, current) reduced from 13.6 (95%
CI 8.1–20.1) in 2008–09, to 7.3 (3.0–12.9) in 2011–12. HCV
prevalence among those who commenced injecting within the last
year was comparable to the derived incidence rates for the
respective years (Figure 2), declining from 20.1% (95% CI 13.9%–
27.6%) in 2008–09 to 8.2% (95% CI 3.4%–16.2%) (P=0.03).
Individual-level analyses
The individual-level associations between uptake of the
interventions and injecting risk behaviour (relationships D, E &
F) are presented in Tables S3, S4, S5, and S6 and summarised in
Table 2: high coverage ($200%) of N/S, spoons, and filters were
significantly associated with approximately 55%, 35% and 20%
reductions, respectively, in the odds of having shared these items in
the last six months. Currently being on OST was associated with a
nearly 80% reduction in the odds of injecting daily or more
frequently in the last six months.
With regard to the associations between sharing injecting
equipment and recent HCV infection (relationships H and I), we
estimated the odds of recent HCV infection to be 7-fold and 3-fold
for sharing needles/syringes and paraphernalia in the last six
months, respectively, as compared with no sharing [2]. The
analysis of the association between frequency of injecting and
recent HCV infection (relationship J) is presented in Table S7: it
was not statistically significant after adjustment for potential
confounders (survey year, homelessness, stimulant injection, time
since onset of injecting and alcohol consumption). Since this is an
indirect association, we also examined and showed that the risk of
sharing either needles/syringes, spoons, or filters, was 3 times
higher among those who injected daily or more frequently as
compared to those who did not (Tables S8, S9 and S10).
Table 5 presents the associations between uptake of harm
reduction interventions and recent HCV infection (relationships
K, L and M in Figure 1). The findings indicated that individuals
with high N/S or high paraphernalia coverage had lower
proportions of recent HCV infection (0.9% and 0.7%, respective-
ly) as compared with those on low coverage of these interventions
(2.4% and 2.0%, respectively). Individuals on OST at the time of
survey had a lower proportion recently infected (1.3%) as
compared with those not on OST (2.5%). The effect of the
weighting by injecting frequency was generally to increase the
differences in incidence between the high and low coverage
groups.
In multivariable unweighted analyses, both high N/S and
paraphernalia coverage were associated with reduced risk of recent
HCV (AOR 0.39, 95% CI 0.19–0.83, P=0.014 and AOR 0.39,
95% CI 0.14–1.12, P=0.081, respectively) relative to those with
low coverage. In weighted analyses, both adjusted odds ratios
moved farther away from null (AORw 0.14, 95% CI 0.04–0.48,
P=0.002 for N/S coverage and AORw 0.11, 95% CI 0.03–0.44,
P=0.002 for paraphernalia coverage). Being on OST at the time
of the survey was not statistically associated with recent infection in
either unweighted or weighted analyses (AOR 0.63, 95% CI 0.35–
1.12; and AORw 0.52, 95% CI 0.23–1.18, respectively).
Model (iv) examined the combined effects of N/S coverage and
OST. With the exception of those who did not inject in the last six
months, there was a general downward gradient in incidence with
increasing coverage of interventions, and this trend was more
apparent in the weighted incidence. In the unweighted analyses,
those with high N/S coverage had lower odds of recent infection,
whether also on OST or not (AOR 0.28, 95% CI 0.08–0.96 and
AOR 0.29, 95% CI 0.11–0.74). This was also the case for the
weighted analyses, although there was a slight difference between
the effect sizes, with those on high N/S coverage and current OST
exhibiting a greater reduction in risk (AORw 0.05, 95% CI 0.01–
0.18) as compared to those on high N/S and no OST (AORw
0.18, 95% CI 0.04–0.87).
Figure 3 presents proportions recently infected with HCV for
the different strata of model (v). The highest incidence of HCV
(3.5% unweighted and 3.9% weighted) was among the baseline
group of those on the lowest coverage of all three interventions.
Among PWID with low coverage of both needles/syringes and
paraphernalia, the results were suggestive of a reduction in risk of
approximately 40% for those on current OST (this can be also
seen by the difference in the height of the two left-hand bars in
Figure 3a and 3b); althoughit was not statistically significant after
adjustment (AOR 0.55, 95% CI 0.27–1.11; AORw 0.58, 95% CI
0.25–1.34). There were no recent infections in the ‘low N/S, high
para’ groups, due to very small numbers in these groups, and
therefore it was not possible to calculate odds ratios. Moving from
low to high N/S coverage was associated with lower HCV
incidence, although the larger difference was seen among those
not on OST (3.5% to 1.0% unweighted; 3.9% to 0.8% weighted)
as compared to those on OST (1.7% to 0.9% unweighted; 2.0% to
0.1% weighted). In unweighted analyses, those who had high N/S
coverage and were on OST, regardless of paraphernalia coverage,
had lower odds of recent infection relative to those on the lowest
coverage of interventions (AOR 0.28, 95% CI 0.08–0.98,
P=0.046 and AOR 0.28, 95% CI 0.08–0.97, P=0.044). This
finding was similar in the weighted analyses (AORw 0.02, 95% CI
0.01–0.09 and AORw 0.07, 95% CI 0.01–0.35 for those with low
and high paraphernalia coverage, respectively). Most of the
confidence intervals for the AORs of the different intervention
coverage groups overlapped, with the exception of the ‘low N/S,
low para, OST’ group (AORw 0.58, 95% CI 0.25–1.34) and the
‘high N/S, low para, OST’ group (AORw 0.02, 95% CI 0.01–
0.09) in weighted analyses.
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New infections and infections averted
The estimated number of new infections per year declined from
1063 (95% CI 591–1682) in 2008 to 566 (95% CI 205–1039) in
2012 (Table 6). With regard to new chronic infections, these have
potentially declined from 787 (95% CI 441–1248) in 2008 to 419
(95% CI 152–774) in 2012. We estimate that approximately 1,400
new infections and 1,000 new chronic infections may have been
averted during 2008–2012.
Discussion
We have observed a decline in HCV incidence among PWID
during a period of development in harm reduction services in
Scotland. This finding is corroborated by a similar trend observed
in prevalence of HCV among recent initiates to injecting, which
can be considered a proxy for incidence. A number of factors are
likely to have contributed to the declining incidence of HCV:
identifying the contributions of individual interventions is the
challenge.
We applied a framework approach to bring together evidence
for all of the steps and relationships on the pathways from
interventions to outcome. Considering first the ecological/group-
level analyses: in terms of the provision of interventions, it would
appear that the largest change was the increase in distribution of
filters and spoons. The contemporaneous increase in the self-
reported uptake of filters and spoons over the three surveys, in
terms of both numbers of items and coverage, would appear to
reflect this change in provision. Furthermore, the increases in
uptake of paraphernalia were mirrored by significant declines in
the self-reported sharing of these items over the period, as would
be expected.
By contrast, the finding of an initial decline in the self-reported
numbers of sterile N/S obtained by individuals is apparently
inconsistent with the relatively stable numbers of needles/syringes
distributed. However, the decrease in self-reported numbers of
needles/syringes obtained by respondents is offset by declines in
the frequency of injecting, such that the proportion reporting high
N/S coverage across the three surveys remained more or less
stable (based on self-report), suggesting that the finding of less
uptake is explained by less need. By contrast, the alternative
measure of coverage (based on service provision) showed an
increase from approximately half to three quarters of PWID with
adequate coverage. Given this was based on stable numbers of N/
S distributed, it was again the declining frequency of injecting that
caused the change (from a mean of approximately 550 injections
per PWID down to 400 in 2011–12). The observed reduction in
Table 3. Group-level analyses: risk behaviour and harm reduction intervention uptake of study sample, by survey.
2008–09 (N=2,629)
2010
(N=3,168)
2011–12
(N=2,154)
Test for difference
between yearsa P value
(i) Intervention uptake (last 6 months)
Currently on OST All PWIDb,c 50% 60% 64% 48.442 ,0.001
PWID, currentb,c 49% 60% 64% 50.564 ,0.001
Median no. N/S obtained in typical week in last 6 months (IQR)c 15 (25) 10 (17) 10 (18) 113.493 ,0.001
Median no. filters obtained in typical week in last 6 months
(IQR)c
0 (8) 8 (20) 10 (19) 794.167 ,0.001
Median no. spoons obtained in typical week in last 6 months
(IQR)c
0 (5) 7.5 (19) 10 (18) 1026.638 ,0.001
Self-report IEP Coveraged
Proportion with adequate N/S coverage ($100%)c 75% 79% 77% 3.271 0.071
Proportion with adequate filter coverage ($100%)c 24% 58% 69% 817.385 ,0.001
Proportion with adequate spoon coverage ($100%)c 20% 58% 70% 972.267 ,0.001
Service provision IEP Coveraged
Proportion with adequate N/S coverage ($100%) 53% 62% 74%
Proportion with adequate filter coverage ($100%) 4% 34% 40%
Proportion with adequate spoon coverage ($100%) 6% 33% 39%
(ii) Risk behaviour (last 6 months)
Injected at least dailyc 63% 54% 49% 73.712 ,0.001
Shared N/Sc 15% 11% 8% 51.497 ,0.001
Mean no. times shared N/S (SD)c 0.89 (4.0) 0.69 (4.2) 0.46 (4.0) F = 5.357 0.005
Mean no. times shared N/S among those who shared (SD)c 5.9 (8.7) 6.5 (11.4) 6.0 (13.0) F = 0.209 0.812
Reused own needle/syringec 64% 59% 45% 131.952 ,0.001
Shared spoonsc 42% 33% 20% 217.652 ,0.001
Shared filtersc 33% 28% 17% 123.088 ,0.001
Shared waterc 31% 29% 21% 48.740 ,0.001
aX2 test for trend for proportions, Kruskal-Wallis test for medians, ANOVA test for means.
bAmong those who cited needle exchange as the reason for visiting the service on the day of recruitment.
cAmong those who reported injecting in the last 6 months.
dSee methods for details. P-values have not been calculated for the second measure of IEP coverage – because of the large numbers, even clinically insignificant
changes would be statistically significant.
doi:10.1371/journal.pone.0104515.t003
Declining HCV Incidence in People Who Inject Drugs
PLOS ONE | www.plosone.org 7 August 2014 | Volume 9 | Issue 8 | e104515
reported N/S sharing is perhaps more consistent with increasing
N/S coverage. Otherwise, the decline in sharing might be
explained by a potential improvement in the quantity/quality of
education that is being provided during injecting equipment
transactions, as recommended in the national guidelines [11],
leading to a greater awareness of the risks of injection. Thus, if
people have usually been obtaining sufficient needles/syringes for
their injections but not using all of them, coverage could feasibly
stay the same while sharing goes down. A similar enigma was
observed for water: self-reported sharing of water declined despite
distribution of sterile water ampoules not having changed [19].
The increase in self-reported uptake of OST among survey
participants also occurred contemporaneously with more or less
stable dispensation of methadone prescriptions. Although we do
not have information on how the PWID population has changed
over the period examined, speculatively, if the PWID population
had decreased, this might explain how the same number of
prescriptions could translate into an increase in the uptake of
Figure 2. Prevalence (among recent onset injectors) and derived incidence of HCV among people who inject drugs in Scotland,
2008 to 2012. The diamonds/circles represent the point estimate and the bars represent the upper and lower 95% confidence intervals. aanti-HCV
prevalence among those who commenced injecting within the past 12 months. bDetermined by applying the estimated pre-seroconversion window
period to the observed number of anti-HCV negative and HCV-RNA positive individuals (see methods for details). Restricted to those who had
injected in the last 6 months.
doi:10.1371/journal.pone.0104515.g002
Table 4. Group-level analyses: HCV prevalence and incidence, by survey.
2008–09 2010 2011–12 X2 test for trend P value
(i) HCV prevalence (n = 2,629) (n = 3,168) (n = 2,154)
HCV prevalencea (95% CI) 54% (52–55%) 56% (54–58%) 53% (51–55%) 0.004 0.951
(ii) HCV incidence
(n = 144) (n = 169) (n = 85)
HCV prevalence among those injecting ,1 yr
(95% CI)
20.1% (13.9–27.6%) 18.3% (12.8–25.0%) 8.2% (3.4–16.2%) 4.711 0.030
(n = 1,140) (n = 1,323) (n = 996)
Recent HCV infection (all PWID)b (95% CI) 2.1% (1.4–3.1%) 1.5% (0.9–2.3%) 0.9% (0.4–1.7%) 5.092 0.024
(n = 933) (n = 1,024) (n = 831)
Recent HCV infection (PWID, current)b,c (95% CI) 2.1% (1.3–3.3%) 1.5% (0.8–2.4%) 1.1% (0.5–2.0%) 3.224 0.073
Derived HCV incidence per 100 PY (all PWID) 13.3 (8.4–19.8) 9.9 (5.5–14.8) 6.1 (2.5–11.1) - -
Derived HCV incidence per 100 PY (PWID, current) 13.6 (8.1–20.1) 9.6 (5.1–15.5) 7.3 (3.0–12.9) - -
CI = confidence interval; PWID = people who inject drugs.
aNumerator includes anti-HCV positives and weak reactives; the denominator is all PWID.
bRecent infection is defined as anti-HCV negative and HCV-RNA positive; the denominator is all anti-HCV negative PWID.
cAmong those who reported injecting in the last 6 months.
doi:10.1371/journal.pone.0104515.t004
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Figure 3. a) Unweighted and b) weighted HCV incidence among PWID in Scotland from pooled survey data (2008 to 2012), by harm reduction
intervention uptake. 95% confidence intervals are indicated by the black bars.
doi:10.1371/journal.pone.0104515.g003
Table 6. Estimated number of new infections and new chronic infections per calendar year based on derived incidence ratesa.
Estimated incidence per 100 PY
(95% CI)
Proportion anti-HCV negative (95%
CI) No. new infections (95% CI)
No. new chronic infectionsb (95%
CI)
2008 13.6 (8.1–20.1) 0.48 (0.46–0.50) 1063 (591–1682) 787 (441–1248)
2009 13.6 (8.1–20.1) 0.48 (0.46–0.50) 1063 (591–1682) 787 (441–1248)
2010 9.6 (5.1–15.5) 0.45 (0.43–0.47) 697 (336–1240) 516 (251–908)
2011 7.3 (3.0–12.9) 0.47 (0.44–0.49) 566 (205–1039) 419 (152–774)
2012 7.3 (3.0–12.9) 0.47 (0.44–0.49) 566 (205–1039) 419 (152–774)
CI = confidence interval; PY = person-years.
aNumber of PWID assumed to be stable during 2008–2012 at 16,000 (95%CI 11,782–20,334).
b26% (95% CI 22–29%) assumed to clear acute infection [26].
doi:10.1371/journal.pone.0104515.t006
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OST. The increased uptake of OST was mirrored by a decrease in
the self-reported frequency of injecting across the three surveys.
From an ecological perspective, we have a situation whereby
data on the provision of interventions, uptake of interventions, and
corresponding risk behaviour usually, but not always, paint a
consistent picture. Thus, while ecological analyses can give us an
overview of trends, they generally do not provide insight into the
relationships and, moreover, can highlight discrepancies in the
findings that need to be further investigated using individual-level
analyses.
In the multivariable analyses for the three interventions
independently, both N/S and paraphernalia coverage were
associated with reduced risk of recent HCV infection, although
it is notable that these models were not adjusted for the other
respective interventions.
The unweighted associations represent risks per individual, and
individuals may have injected few or many times. Several of the
associations that were not significant in unweighted analyses
became significant in weighted analyses, and indeed many of the
effect sizes also changed, indicating that the frequency of injecting
of individuals in particular intervention/outcome groups is
potentially obscuring some of the intervention impact in the
unweighted models. For example, the AOR for high N/S
coverage reduced from 0.39 to 0.14; this was because those with
low N/S coverage – in particular, those with incident infection –
reported injecting more frequently, whereas those with high N/S
coverage – also the incident infections in particular – reported
injecting less frequently. The weighting therefore had the effect of
amplifying the difference in the proportion of recent infections
between the low and high coverage groups, which moved the
effect size further from null.
We did not observe a significant association between uptake of
OST alone and incident HCV. It is possible that we had
insufficient power to detect an effect, given that OST coverage is
so high in our study population. Another consideration is that the
association between OST and HCV is an indirect one, since OST
affects frequency of injecting, which is not in itself a mode of HCV
transmission (as is sharing needles/syringes). The theory is that
higher OST uptake should reduce HCV risk, by reducing the
frequency of injecting and, consequently, the probability of sharing
injecting equipment. Our analyses confirmed that OST was
associated with a reduced frequency of injecting, and that lower
frequency of injecting was associated with less sharing of all types
of equipment. From the unadjusted incidence, it appeared that
OST had a larger effect among those on low coverage of N/S and
paraphernalia, which would be expected, given that the impact of
injecting frequency on HCV transmission would be augmented if
insufficient sterile equipment was being used.
Despite no effect of OST alone, it was associated with recent
HCV in combination with N/S: being on OST and having high
coverage N/S was associated with a greater reduction in risk of
recent HCV (in weighted analyses, a 95% reduction in risk) as
compared with either of the separate intervention effects, although
our analysis was underpowered to demonstrate statistical signifi-
cance.
In the combined interventions model stratified for parapherna-
lia, there was little difference in effect size between the groups with
low and high paraphernalia coverage when the other interventions
wereunchanged.Reasons for the lack of association between
paraphernalia coverage and recent HCV could be:that uptake of
paraphernalia is associated with a lower reduction in sharing as
compared with uptake of needles/syringes (i.e. although PWID are
obtaining paraphernalia from services, they are not using all of
them); and/or that there is a lower risk of HCV transmission
associated with sharing paraphernalia, such that a reduction in
sharing paraphernalia might have less of an effect on transmission
as compared with a reduction in needle/syringe sharing.
Our findings regarding paraphernalia coverage do not neces-
sarily mean that providing paraphernalia is ineffective with regard
to preventing HCV transmission. To evaluate the impact of sterile
paraphernalia, one would ideally compare the incidence between
high and low paraphernalia coverage groups solely among those
with low N/S coverage. This was not possible here because there
were too few people in these groups (approximately 50 in total),
due to the fact that uptake of paraphernalia generally goes hand-
in-hand with uptake of needles/syringes. It is possible that our
analyses are underpowered to detect an effect and that pooling
further sweeps of NESI would allow us to examine this with a
larger sample size. A further consideration is that, for sharing
paraphernalia to pose a risk of HCV transmission, it must first
become contaminated with blood from a used needle/syringe.
Thus, the risk from sharing paraphernalia is dependent on the
rates of reuse or sharing of needles/syringes, both of which have
declined over the period of study. If the rates of needle/syringe
sharing or reuse in Scotland were to rise, the availability of sterile
paraphernalia might become more critical in preventing HCV
transmission.
Although we have observed encouraging signs in the direction
of HCV incidence, we have not seen any changes in HCV
prevalence. A mathematical modelling study has suggested that
high coverage levels of both OST and NSP would need to be
sustained for a 15-year period in order to reduce prevalence by a
third [9]. Thus, it may be the case that it will take many years of a
sustained reduction in HCV transmission before any changes in
prevalence are observed.
Comparability of our results
Scotland is one of few countries world-wide to have a
surveillance system, with national coverage, that generates serial
measures of HCV incidence. While one-off studies have been done
to measure incidence in regional populations of PWID in the UK
[23,27,28], it is not known whether the decline in HCV incidence
observed here has been replicated elsewhere in the UK.
Internationally, others have reported reductions in HCV incidence
among PWID; however, these have tended to be over very long
periods of time (often decades), restricted to regional populations,
involving smaller sample sizes than ours, and/or involving lower
coverage of interventions as compared with Scotland [29,30].
Furthermore, it is notable that the latter declines in HCV occurred
within the context of major shifts away from heroin and/or
injecting [29,31]. Although we have observed a reduction in
frequency of injecting (related to increased prescribed methadone),
this is still in context of a country with major heroin injecting
problem [25]. Thus, other countries with persistent injecting
populations can draw inferences on the potential impact of high
coverage IEP and OST from our findings.
Our findings regarding OST are in contrast to other reports in
the literature, which have found a significant association between
OST uptake and HCV. In a synthesis of UK data, Turner et al.
[7] found that receiving OST was associated with an approxi-
mately 60% reduction in odds of incident HCV (AOR 0.41,
95%CI: 0.21–0.82). Turner et al. also found that high N/S
coverage was associated with a reduced risk of recent HCV (AOR
0.48, 95% CI: 0.25–0.93), similar to our adjusted (unweighted)
effect size.
Finally, Turner et al. determined that ‘full’ harm reduction (i.e.
on OST plus high N/S coverage) reduced the odds of new HCV
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infection by nearly 80% (AOR=0.21, 95% CI: 0.08–0.52), which
is similar to our (unweighted) AOR for combined coverage.
Strengths and limitations
Whereas most analyses take either an ecological or an
individual-level approach, in this study we have attempted to
consider both types of evidence in conjunction. Constructing a
coherent narrative from the ecological data can be difficult,
particularly when trying to reconcile data from different sources,
such as service provision and selected population samples. The
limitations of drawing inferences solely from ecological analysis are
also apparent from this analysis; on the other hand, considering
just the individual-level evidence does not give us the overview of
trends in provision, uptake, risk behaviour, and HCV incidence.
Although these types of evidence will never provide the same level
of confidence, in terms of a causal association between interven-
tion(s) and outcome, as a randomised controlled trial, the
triangulation of evidence generated by different study designs is
understood to increase confidence [17]. In the ecological analyses,
other contemporaneous interventions or factors could potentially
have been responsible for some of the observed changes; the
individual analyses provide validation for some of these associa-
tions. For example, that the uptake of interventions is associated
with reduced risk behaviour at the individual-level means we can
therefore be more confident that the changes in risk behaviour
observed were due to the provision of the interventions. There are
nevertheless factors that were outside the scope of these analyses
that could have had an impact on HCV incidence; for example,
HCV antiviral treatment. However, treatment rates remain low in
this population group and so treatment, alone, is unlikely to
account fully for the reduced HCV incidence. Nevertheless, the
potential impact of HCV treatment has been demonstrated in
mathematical models [32,33] and it is possible that, in combina-
tion with IEP and OST, it contributed to the reduction in HCV
transmission observed here.
Selection bias can be an issue in non-randomised studies. The
NESI studies recruited participants at services that provide sterile
injecting equipment (and often dispense methadone also). This
approach may have excluded ‘high risk’ PWID who are not in
contact with services,which may have resulted in an underestimate
of HCV incidence (assumeingthat those not attending services are
at greater risk of HCV infection) and an underestimate of
intervention impact (assuming those not attending services would
have contributed to the group with recent infection and low
coverage of interventions). However, that we have demonstrated a
decline in incidence among those attending services is nevertheless
and important finding in itself, and is indicative that these services
are having an impact among attendees. There is also the issue of
the comparability of consecutive NESI surveys. While we
attempted to maximise consistency in recruitment across surveys,
it was not always possible to recruit the from same services year-
on-year. There are indications that the PWID population in
Scotland is an ageing cohort: we have observed an increase in the
average age and time since onset of injecting over the years. That
older PWID are less likely to engage in risk behaviour may explain
some of the downward trends in risk behaviour and incidence.
However, we do not believe that this would be sufficient to explain
the sharpness of the downward trends observed, and furthermore
the finding of a declining prevalence among those who had
commenced injecting with the previous year provides evidence
that this decline in HCV is also occurring among newer PWID. In
addition, the multivariate models demonstrated associations with
harm reduction interventions even after adjustment for time since
onset of injecting, suggesting that the latter does not fully account
for the observed changes in HCV incidence.
Despite our large sample size, we detected only just over 50
recent infections in the pooled analysis: thus, the lack of statistical
significance in some cases – particularly when examining
interventions classified into multiple strata – may have been a
result of lack of power. In a scenario of declining HCV incidence,
increasingly large sample sizes will be required to detect
increasingly small numbers of recent infections.
The derived incidence estimates are reliant on an accurate
figure for the duration of the pre-seroconversion window period,
around which there is uncertainty [24]. We will not have captured
persons who had recently seroconverted at the time of interview;
however, the incidence calculation takes this underestimation into
account. We would generally not detect re-infections: people who
hadbeen infected in the past would have HCV antibody and
would have been classed as prevalent infections. By contrast, some
of the recent infections may have been individuals who cleared
infection and lost antibodies (i) over time [34] or (ii) due to HIV-
coinfection [35]. However, these are unlikely to account for many
recent infections since (i) the majority of recent infections were
among PWID with less than five years injecting and (ii) HIV
prevalence is very low in this population [36].
In relation to OST, one of the limitations of this study is that it is
not specifically designed to measure the impact of this interven-
tion. Questions on methadone dosage have not been asked
consistently across the surveys, therefore it was not possible to
examine the association between dosage and recent HCV;
moreover, dosage itself is a problematic measure, as what
constitutes an adequate dosage can vary greatly from person to
person. At the provision level, the absence of available data on
persons receiving methadone mixture meant that numbers of
methadone mixture prescriptions were presented instead: these
could be misleading because a single prescription can indicate
single or multiple dose(s). Assuming that prescribing practices have
not changed drastically over the period of study, then the observed
trends are still likely to be valid.
Finally, the self-reported nature of the risk behaviours and
uptake of harm reduction interventions is a limitation. While the
self-reported data likely contains an element of inaccuracy due to
difficulty with respondents’ ability to recall events, the consistency
of the associations between self-reported behaviour and biological
markers (both HCV prevalence and incidence) is high, lending
credence to the validity of the data.
Conclusions
These data provide evidence of a downward trend in HCV
incidence among PWID in Scotland. The two different approach-
es used in this analysis strengthen the inference that the changes in
HCV incidence are attributable to harm reduction interventions –
particularly N/S and OST combined. Future monitoring of
PWID will be required to establish whether the downward
direction in HCV transmission among PWID in Scotland is
sustained.
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